Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 32Ovarian Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 13Fallopian Tube Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Endometrial Neoplasms 7Colonic Neoplasms 7Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Biliary Tract Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Mouth Neoplasms 2Meningioma 2Lymphoid Interstitial Pneumonia 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Virus Infections × Bevacizumab × 30 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡